-
今开：--
昨收：--
-
今日区间：--
52周区间：--
-
成交量：--
成交额：--
-
市 值：--
市盈率：--
-
振幅：
每股收益：
成交量
董事会
- John V. Oyler
- John V. Oyler was the founder of Telephia, Inc. (1997), serving as President; BioDuro LLC (2005), serving as Chief Executive Officer; and BeOne Medicines Ltd. (2010), serving as Chairman & Chief Executive Officer. Mr. Oyler is currently the CEO, CFO, Secretary & Director at BeiGene USA, Inc. Former positions include Co-Chief Executive Officer at Genta, Inc. (1997-1998), Chief Executive Officer at Galenea Corp. (2002-2004), Director at Biotechnology Innovation Organization (2019-2024), Principal at McKinsey & Co., Inc., Vice President-Operations at Walden Laboratories, Inc., and Principal at Sidney Kimmel Cancer Center. Education includes an MBA from Stanford University (1996) and an undergraduate degree from the Massachusetts Institute of Technology (1990).
-
- John V. Oyler
- John V. Oyler was the founder of Telephia, Inc. (1997), serving as President; BioDuro LLC (2005), serving as Chief Executive Officer; and BeOne Medicines Ltd. (2010), serving as Chairman & Chief Executive Officer. Mr. Oyler is currently the CEO, CFO, Secretary & Director at BeiGene USA, Inc. Former positions include Co-Chief Executive Officer at Genta, Inc. (1997-1998), Chief Executive Officer at Galenea Corp. (2002-2004), Director at Biotechnology Innovation Organization (2019-2024), Principal at McKinsey & Co., Inc., Vice President-Operations at Walden Laboratories, Inc., and Principal at Sidney Kimmel Cancer Center. Education includes an MBA from Stanford University (1996) and an undergraduate degree from the Massachusetts Institute of Technology (1990).
-
- Michael J. Goller
- Michael J. Goller is currently Director at DBV Technologies SA since 2015, Independent Non-Executive Director at BeOne Medicines Ltd. since 2015, Director at Terremoto Biosciences, Inc., Independent Director at Replimune Group, Inc. starting in 2025, and Partner at Baker Bros. Advisors LP since 2005. Former roles include Director at diaDexus, Inc. from 2005 to 2010, Director at Levo Therapeutics, Inc. from 2017 to 2019, Associate at J.P. Morgan Partners LLC from 1993 to 2003, and Investment Banker at Merrill Lynch & Co., Inc. from 1997 to 1999. Education includes graduate and Masters of Business Administration degrees from The Wharton School of the University of Pennsylvania and an undergraduate degree from The Pennsylvania State University conferred in 1997.
-
- Ranjeev Krishana
- Ranjeev Krishana is currently Director at Sironax Ltd., Lead Independent Director at BeOne Medicines Ltd. since 2014, and Head of International Investments at Baker Bros. Advisors LP. Formerly, Mr. Krishana was Director at Pfizer Inc. in 2007, Senior Regional Director at Pfizer Inc. in 2011, Non-Executive Director at Immunocore Holdings Plc from 2024 to 2025, Consultant at Andersen Consulting (Minnesota) in 1997, and Manager at Accenture LLC in 2001. Education includes a graduate degree from Harvard University conferred in 2001 and an undergraduate degree from Brown University conferred in 1995.
-
- Qing Qing Yi
- Qing Qing Yi currently works at Hanhui Pharmaceutical Co. Ltd. (China), as Vice Chairman from 2017, JD Health International, Inc., as Non-Executive Director from 2020, BeOne Medicines Ltd., as Independent Non-Executive Director from 2014, and Hillhouse Capital Group Ltd., as Partner. Mr. Yi also formerly worked at Genor Biopharma Holdings Ltd., as Chairman from 2018 to 2021, Shanghai Junshi Biosciences Co., Ltd., as Non-Executive Director from 2016 to 2021, Gossamer Bio, Inc., as Director, and HiberCell, Inc., as Director. Mr. Yi received his Masters Business Admin degree in 2003 from the University of Southern California and undergraduate degree in 1995 from Shanghai Maritime University.
-
- Xiao Dong Wang
- Xiao Dong Wang is the founder of Joyant Pharmaceuticals, Inc. (2004), National Institute of Biological Sciences (2003), Sironax Ltd. (2017), and BeOne Medicines Ltd. (2010). Current jobs include Non-Executive Director at Clover Biopharmaceuticals Ltd. (2021), Foreign Associate at Chinese Academy of Sciences (2013), Member at National Academy of Sciences (2004), and Professor at Tsinghua University (2020). Former jobs include Professor at Howard Hughes Medical Institute, Inc. and Professor at The University of Texas Southwestern Medical Center (2001-2010). Education includes an undergraduate degree from Beijing Normal University (1984) and a doctorate from The University of Texas Southwestern Medical Center.
-
- Xiao Dong Wang
- Xiao Dong Wang is the founder of Joyant Pharmaceuticals, Inc. (2004), National Institute of Biological Sciences (2003), Sironax Ltd. (2017), and BeOne Medicines Ltd. (2010). Current jobs include Non-Executive Director at Clover Biopharmaceuticals Ltd. (2021), Foreign Associate at Chinese Academy of Sciences (2013), Member at National Academy of Sciences (2004), and Professor at Tsinghua University (2020). Former jobs include Professor at Howard Hughes Medical Institute, Inc. and Professor at The University of Texas Southwestern Medical Center (2001-2010). Education includes an undergraduate degree from Beijing Normal University (1984) and a doctorate from The University of Texas Southwestern Medical Center.
-
- Anthony C. Hooper
- Anthony C. Hooper currently works at MannKind Corp., as Independent Director from 2020, HealthCare Institute of New Jersey, as Director, The American Institute for Stuttering, as Director, The Impact Young Lives Foundation, as Director, Amplity, Inc., as Director from 2020, BeOne Medicines Ltd., as Independent Non-Executive Director from 2023, and American Heart Association (New York), as Executive Driector. Mr. Hooper also formerly worked at American Foundation for Suicide Prevention, as Chairman, Capital Health System, Inc., as Executive Director, National Pharmaceutical Council, as Director, Amgen, Inc., as Executive VP-Global Commercial Operations from 2011 to 2018, Bristol Myers Squibb Co., as Senior Vice President-Global Commercial Operations in 2011, John Wyeth & Brother Ltd., as Assistant Vice President-Marketing, and Wyeth Laboratories, Inc., as Assistant Vice President-Global Marketing. Mr. Hooper received his graduate degree in 1978 and Masters Business Admin degree in 1988 from the University of South Africa.
-
- Corazon Dating Sanders
- Corazon Dating Sanders currently works at AbGenomics International, Inc., as Director, Ultragenyx Pharmaceutical, Inc., as Independent Director from 2021, BeOne Medicines Ltd., as Independent Non-Executive Director from 2020, Legend Biotech Corp., as Independent Director, Altrubio, Inc., as Director from 2020, and Fred Hutchinson Cancer Research Center, as Trustee from 2022. Dr. Sanders also formerly worked at Fred Hutchinson Cancer Research Center, as Director, Transcelerate Biopharma, Inc., as Director, Molecular Templates, Inc., as Independent Director from 2019 to 2024, Genentech, Inc., as Senior Vice President & Global Head-PD Innovation from 2012 to 2017, and Juno Therapeutics, Inc., as Executive Vice President-Development Operations from 2017 to 2018. Dr. Sanders received her undergraduate degree and graduate degree from the University of the Philippines and graduate degree and doctorate degree from The Wharton School of the University of Pennsylvania.
-
- Alessandro Riva
- Alessandro Riva was the founder of Intima Bioscience, Inc., founded in 2021, where the title held was Chief Executive Officer from 2021 to 2023. Dr. Riva is also the founder of Breast Cancer International Research Group Ltd.,Cancer International Research Group.. Dr. Riva is Chairman & Chief Executive Officer at Transgene SA since 2023, Independent Director at Century Therapeutics, Inc. since 2021, Independent Non-Executive Director at BeOne Medicines Ltd. since 2022, and Independent Director at Bicycle Therapeutics Plc starting in 2025. Former positions include Chief Executive Officer-Innovation Business at Glenmark Pharmaceuticals Ltd., Director at Ichnos Glenmark Innovation, Inc. in 2021, Director at Century Therapeutics, Inc. in 2021, Executive VP-Oncology Therapeutics at Gilead Sciences, Inc. from 2017 to 2019, President at Novartis Oncology, Inc. from 2005 to 2016, VP, Head-Oncology Development & Medical Affairs at Novartis AG from 2005 to 2016, and EVP, Head-Oncology Development & Medical Affairs at Novartis Pharmaceuticals Corp. Education includes undergraduate and doctorate degrees from the University of Milan.
-
- Margaret Han Dugan
- Margaret Han Dugan is currently an Independent Non-Executive Director at BeOne Medicines Ltd. since 2022 and will be Chief Medical Officer at Whitehawk Therapeutics, Inc. starting in 2025. Former roles include Chief Medical Officer at Dracen Pharmaceuticals, Inc. from 2018 to 2023, Chief Medical Officer at Schr dinger, Inc., Senior VP & Head-Global Program Oncology at Novartis Pharmaceuticals Corp., Director-Oncology Clinical Research at Schering-Plough Corp., and Deputy Director-Clinical Research Oncology at Wyeth Holdings LLC. Education includes undergraduate and doctorate degrees from New York University, conferred in 1977 and 1981 respectively.
-
- Olivier Brandicourt
- Olivier Brandicourt is currently Chairman at AvenCell Therapeutics, Inc., Independent Director at Alnylam Pharmaceuticals, Inc. since 2020, Director at National Committee on United States-China Relations, Inc., Independent Non-Executive Director at BeOne Medicines Ltd. since 2024, Director at Dewpoint Therapeutics, Inc. since 2020, Independent Director at Vaxcyte, Inc. starting 2025, and Council Member at International Federation of Pharmaceutical Manufacturers. Former positions include Chief Executive Officer at Sanofi-Aventis (Singapore) Pte Ltd., Chief Executive Officer & Director at Sanofi from 2015 to 2019, Chairman at Pharmaceutical Research & Manufacturers of America in 2019, Vice Chairman at The Children's Aid Society, Inc., Chairman at Sanofi Biotechnology SAS, Chairman-Management Board at Bayer HealthCare AG from 2013 to 2015, Managing Director at Pfizer Manufacturing Ireland Unlimited Co. in 2007, Managing Director at Pfizer Ltd. from 2004 to 2007, Independent Non-Executive Director at BenevolentAI SA from 2022 to 2024, President & General Manager-Emerging Markets at Pfizer Inc. in 2013, Vice President at Warner-Lambert Co. from 1998 to 2000, Executive Council Member at Bayer AG, Vice President & Member at European Federation of Pharmaceutical Industries & Assns, Vice President & General Manager at Parke, Davis & Co. LLC from 1998 to 2000, and Principal at Odyssey Acquisition SA. Education includes graduate and doctorate degrees from Universite Paris Est Creteil Val De Marne and an undergraduate degree from Université de Paris 5 René Descartes.
-
- Shalini Sharp
- Shalini Sharp is currently Chairman at Mahzi Therapeutics, Inc., Independent Director at Neurocrine Biosciences, Inc. since 2020, Director at Alameda County Community Food Bank, Independent Director at Organon & Co. since 2021, Independent Non-Executive Director at BeOne Medicines Ltd. since 2024, and Independent Director at Septerna, Inc. since 2024. Former roles include Chief Executive Officer at Elan Corp. Plc from 2001 to 2003, Independent Director at Global Alliance for TB Drug Development from 2015 to 2022, Independent Director at Agenus, Inc. from 2012 to 2018, Independent Director at Array BioPharma, Inc. from 2017 to 2019, Independent Director at Precision BioSciences, Inc. from 2018 to 2022, Independent Director at Sutro Biopharma, Inc. from 2018 to 2023, Independent Director at Mirati Therapeutics, Inc. from 2021 to 2024, Director at Panacea Acquisition Corp. from 2020 to 2021, Chief of Staff at Elan Pharmaceuticals LLC from 1998 to 2003, Chief Financial Officer & Senior VP-Finance at Ultragenyx Pharmaceutical, Inc. from 2012 to 2020, and Treasurer & Vice President at Dimension Therapeutics, Inc. Education includes an MBA from Harvard Business School and undergraduate studies at Harvard College.
-